Memantine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is believed to work by acting on NMDA receptors, working as pore blockers of these ion channels. See also [https://en.wikipedia.org/wiki/Memantine]. | Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is believed to work by acting on NMDA receptors, working as pore blockers of these ion channels. See also [https://en.wikipedia.org/wiki/Memantine]. | ||
<scene name='96/963765/Overall/1'>Memantine-bound GluN1a-GluN2B NMDA receptors</scene> ([[7sad]]); GluN1a subunits are in cyan, GluN2B subunits are in green, and memantine is in magenta. | <scene name='96/963765/Overall/1'>Memantine-bound GluN1a-GluN2B NMDA receptors</scene> ([[7sad]]); GluN1a subunits are in cyan, GluN2B subunits are in green, and memantine is in magenta. <scene name='96/963765/Binding_site/1'>Memantine binding site</scene>. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 13:45, 30 April 2023
Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is believed to work by acting on NMDA receptors, working as pore blockers of these ion channels. See also [1]. (7sad); GluN1a subunits are in cyan, GluN2B subunits are in green, and memantine is in magenta. .
|
| ||||||||||